Monoclonal antibody | |
---|---|
Type | ? |
Clinical data | |
Other names | IST-1097; KappaMab; MDX-1097 |
Identifiers | |
CAS Number |
MDX-1097 (formerly called IST-1097, now called KappaMab) is a monoclonal antibody therapy that in 2023 has been assessed in a Phase IIb clinical trial in conjunction with lenalidomide and dexamethasone as a treatment for multiple myeloma, a type of white blood cell cancer. [1] [2] MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd. [3] In 2015, Haemalogix Ltd acquired the rights to MDX-1097 and are taking it through clinical testing. [4]
Originally, a mouse (murine) antibody was used for initial experiments. This murine monoclonal antibody, called K-1-21, was raised against purified human kappa Bence Jones proteins (BJP). [5] K-1-21 was shown to be specific for a cell-surface antigen that was named kappa myeloma antigen (KMA). KMA was found on malignant B cells (plasma cells) isolated from the bone marrow of patients with kappa restricted multiple myeloma (kMM), lymphoma and Waldenström macroglobulinemia. [5] [6] KMA was also detected in cell culture on the surface of human myeloma cell lines derived from patients with kappa restricted myeloma (kHMCLs). The K-1-21 antibody was re-named mKap.
The next step was to produce an antibody for use in humans that was based on the murine version. The heavy and light chain variable region genes (VH and Vk) of MDX-1097 were isolated from mKap hybridoma cells using recombinant DNA methodologies. [7] MDX-1097, a chimeric (murine plus human) monoclonal antibody, was manufactured according by Medarex Inc. (subsidiary of Bristol-Myers Squibb). MDX-1097 has retained the specificity and affinity observed for mKap. MDX-1097 has been used in the clinical trials described below, as well as in vitro studies.
KMA is a membrane-bound form of free kappa light chain on malignant B-cells, in-vitro activated B cells and rare tonsillar B-cells. [8] [9] [10] KMA is not found on normal human leucocytes. [5] [10] [7] KappaMab (MDX-1097) is specific for KMA and binds to a unique conformational epitope in the kappa constant region that is presented when kappa free light chain (kFLC) associates with sphingomyelin in the cell membrane. [10] [11] KappaMab does not bind to kappa immunoglobulin (Igκ) and it has a 5-fold higher affinity for membrane-bound KMA (IC50 4nM) when compared to serum kappa Free Light Chain (IC50 20nM). [10] Moreover, in vitro studies demonstrated that KM induces selective antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) of kappa-positive MM cells and that lenalidomide (LEN) exposure upregulates KMA expression on MM cells promoting enhanced KM-induced NK-mediated ADCC. [10]
In an initial Phase 1 clinical trial, [12] MDX-1097 was administered intravenously to multiple myeloma patients with stable kappa-type disease, with doses ranging from 0.3 mg/kg to 10.0 mg/kg. The study primarily aimed to evaluate MDX-1097's safety profile across these dose levels. [13]
In a Phase 2a clinical trial involving 19 patients with stable kappa-type multiple myeloma, MDX-1097 was administered at a dose of 10 mg/kg weekly for 8 doses to assess safety and efficacy., [14] [15]
In a Phase 2b investigator-initiated clinical trial, repeated doses of KappaMab were administered either alone or in combination with lenalidomide and dexamethasone to patients with kappa-type relapsed, refractory multiple myeloma (MM). [1] The study, conducted across multiple centers, aimed to assess safety and efficacy in both treatment cohorts. [2]
Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. Often, no symptoms are noticed initially. As it progresses, bone pain, anemia, kidney dysfunction, and infections may occur. Complications may include hypercalcemia and amyloidosis.
Theralizumab is an immunomodulatory drug developed by Thomas Hünig of the University of Würzburg. It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by Parexel in London in March 2006. The developing company, TeGenero Immuno Therapeutics, went bankrupt later that year. The commercial rights were then acquired by a Russian startup, TheraMAB. The drug was renamed TAB08. Phase I and II clinical trials have been completed for arthritis and clinical trials have been initiated for cancer.
Monoclonal antibodies (mAbs) have varied therapeutic uses. It is possible to create a mAb that binds specifically to almost any extracellular target, such as cell surface proteins and cytokines. They can be used to render their target ineffective, to induce a specific cell signal, to cause the immune system to attack specific cells, or to bring a drug to a specific cell type.
Technetium (99mTc) arcitumomab is a drug used for the diagnostic imaging of colorectal cancers, marketed by Immunomedics. It consists of the Fab' fragment of a monoclonal antibody and a radionuclide, technetium-99m.
Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer. It targets TRAIL-R1, also known as DR4, which is expressed on the surface of many tumor cell types.
In hematology, plasma cell dyscrasias are a spectrum of progressively more severe monoclonal gammopathies in which a clone or multiple clones of pre-malignant or malignant plasma cells over-produce and secrete into the blood stream a myeloma protein, i.e. an abnormal monoclonal antibody or portion thereof. The exception to this rule is the disorder termed non-secretory multiple myeloma; this disorder is a form of plasma cell dyscrasia in which no myeloma protein is detected in serum or urine of individuals who have clear evidence of an increase in clonal bone marrow plasma cells and/or evidence of clonal plasma cell-mediated tissue injury. Here, a clone of plasma cells refers to group of plasma cells that are abnormal in that they have an identical genetic identity and therefore are descendants of a single genetically distinct ancestor cell.
Amyloid light-chain (AL) amyloidosis, also known as primary amyloidosis, is the most common form of systemic amyloidosis. The disease is caused when a person's antibody-producing cells do not function properly and produce abnormal protein fibers made of components of antibodies called light chains. These light chains come together to form amyloid deposits which can cause serious damage to different organs. An abnormal light chain in urine is known as Bence Jones protein.
Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor. Administration of elotuzumab is done intravenously. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen. It is being developed by Bristol Myers Squibb and AbbVie.
Milatuzumab is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
A trifunctional antibody is a monoclonal antibody with binding sites for two different antigens, typically CD3 and a tumor antigen, making it a type of bispecific monoclonal antibody. In addition, its intact Fc-part can bind to an Fc receptor on accessory cells like conventional monospecific antibodies. The net effect is that this type of drug links T cells and monocytes/macrophages, natural killer cells, dendritic cells or other Fc receptor expressing cells to the tumor cells, leading to their destruction.
Carfilzomib, sold under the brand name Kyprolis, is an anti-cancer medication acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin. It was developed by Onyx Pharmaceuticals.
Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.
Daratumumab, sold under the brand name Darzalex, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.
Pidilizumab is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases. Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule. Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.
Smouldering myeloma is a disease classified as intermediate in a spectrum of step-wise progressive diseases termed plasma cell dyscrasias. In this spectrum of diseases, a clone of plasma cells secreting monoclonal paraprotein causes the relatively benign disease of monoclonal gammopathy of undetermined significance. This clone proliferates and may slowly evolve into more aggressive sub-clones that cause smouldering multiple myeloma. Further and more rapid evolution causes the overtly malignant stage of multiple myeloma and can subsequently lead to the extremely malignant stage of secondary plasma cell leukemia. Thus, some patients with smouldering myeloma progress to multiple myeloma and plasma cell leukemia. Smouldering myeloma, however, is not a malignant disease. It is characterised as a pre-malignant disease that lacks symptoms but is associated with bone marrow biopsy showing the presence of an abnormal number of clonal myeloma cells, blood and/or urine containing a myeloma protein, and a significant risk of developing into a malignant disease.
Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma.
Ixazomib is a drug for the treatment of multiple myeloma, a type of white blood cell cancer, in combination with other drugs. It is taken by mouth in the form of capsules.
Melphalan flufenamide, sold under the brand names Pepaxto and Pepaxti, is an anticancer medication used to treat multiple myeloma.
Selinexor sold under the brand name Xpovio among others, is a selective inhibitor of nuclear export used as an anti-cancer medication. It works by blocking the action of exportin 1 and thus blocking the transport of several proteins involved in cancer-cell growth from the cell nucleus to the cytoplasm, which ultimately arrests the cell cycle and leads to apoptosis. It is the first drug with this mechanism of action.
Serum B-cell maturation antigen (sBCMA) is the cleaved form of B-cell maturation antigen (BCMA), found at low levels in the serum of normal patients and generally elevated in patients with multiple myeloma (MM). Changes in sBCMA levels have been found to correlate with a MM patient’s clinical status in response to treatment.